Edition:
United States

Stemline Therapeutics Inc (STML.OQ)

STML.OQ on NASDAQ Stock Exchange Capital Market

9.10USD
4:00pm EDT
Change (% chg)

$0.35 (+4.00%)
Prev Close
$8.75
Open
$8.80
Day's High
$9.15
Day's Low
$8.75
Volume
47,762
Avg. Vol
85,428
52-wk High
$14.60
52-wk Low
$4.80

Latest Key Developments (Source: Significant Developments)

Stemline Therapeutics prices $45 mln public offering of common stock
Friday, 20 Jan 2017 09:00am EST 

Stemline Therapeutics Inc : Stemline Therapeutics prices $45 million public offering of common stock . Says public offering of 4.50 million common shares priced at $10.00per share .Offering is expected to close on January 25, 2017.  Full Article

Stemline Therapeutics announces proposed public offering of common stock
Thursday, 19 Jan 2017 04:04pm EST 

Stemline Therapeutics Inc : Stemline Therapeutics announces proposed public offering of common stock .Stemline Therapeutics Inc says intends to use net proceeds from public offering for clinical, regulatory, manufacturing, among others.  Full Article

Stemline Therapeutics reports oral presentation of sl-701 phase 2 data in second-line glioblastoma at the 21st annual meeting of the society of neuro-oncology (sno)
Monday, 21 Nov 2016 07:30am EST 

Stemline Therapeutics Inc : Stemline Therapeutics Inc- sl-701 was found to be safe and well-tolerated . Stemline Therapeutics Inc- additional clinical data updates are expected next year .Press release - Stemline Therapeutics announces oral presentation of sl-701 phase 2 data in second-line glioblastoma at the 21st annual meeting of the society of neuro-oncology (sno).  Full Article

Stemline Therapeutics Q2 loss per share $0.52
Thursday, 4 Aug 2016 07:59am EDT 

Stemline Therapeutics Inc : Q2 loss per share $0.52 . Stemline Therapeutics reports second quarter 2016 financial results and highlights recent clinical progress .Q2 earnings per share view $-0.55 -- Thomson Reuters I/B/E/S.  Full Article

Stemline Therapeutics reports Q1 loss per share $0.51
Monday, 9 May 2016 08:00am EDT 

Stemline Therapeutics Inc : Stemline Therapeutics reports first quarter 2016 financial results . Q1 loss per share $0.51 .Q1 earnings per share view $-0.59 -- Thomson Reuters I/B/E/S.  Full Article

Stemline Therapeutics Inc announces SL-401 receives EU Orphan Drug designation for treatment of BPDCN
Monday, 2 Nov 2015 08:01am EST 

Stemline Therapeutics Inc:Says European Medicines Agency has granted Orphan Drug designation to SL-401 for the treatment of blastic plasmacytoid dendritic cell neoplasm.Stemline is evaluating SL-401 in multiple clinical programs, including an ongoing pivotal trial in BPDCN as well as trials in additional hematological cancers.  Full Article

Stemline Therapeutics Inc announces SL-401 receives eu orphan drug designation for treatment of acute myeloid leukemia
Thursday, 10 Sep 2015 08:00am EDT 

Stemline Therapeutics Inc:Announces SL-401 receives EU orphan drug designation for treatment of acute myeloid leukemia (AML).Says is evaluating SL-401 in three trials across 7 different indications.  Full Article

More From Around the Web

BRIEF-Stemline Therapeutics reports completion of enrollment in stage 3 sl-401 pivotal trial in BPDCN

* Stemline Therapeutics announces completion of enrollment in stage 3 of the sl-401 pivotal trial in bpdcn